

- Nasreddine, Z. S., Phillips, N. A., Bédirian, V., Charbonneau, S., Whitehead, V., Collin, I., Cummings, J. L., & Chertkow, H. (2005). The Montreal Cognitive Assessment (MoCA): A brief screening tool for mild cognitive impairment. *Journal of the American Geriatrics Society*, 53(4), 695–699.
- Nightingale, S., Winston, A., Letendre, S., Michael, B. D., McArthur, J. C., Khoo, S., Solomon, T., & Robertson, K. (2023). HIV-associated neurocognitive disorders in the modern antiretroviral era. *The Lancet Neurology*, 22(5), 431–446.
- Olmedo-Saura, M., Tabrizi, S. J., & Wild, E. J. (2025). Emerging therapeutics for Huntington's disease. *Nature Reviews Drug Discovery*, 24(2), 112–130.
- Petersen, R. C., Lopez, O., Armstrong, M. J., Getchius, T. S. D., Ganguli, M., Gloss, D., Gronseth, G., Marson, D., Pringsheim, T., Day, G. S., et al. (2024). Practice guideline update summary: Mild cognitive impairment. *Neurology*, 102(4), e200–e218.
- Ropper, A. H., Samuels, M. A., Klein, J. P., & Prasad, S. (2023). *Adams and Victor's Principles of Neurology* (12th ed.). McGraw-Hill.
- Saft, C., Orth, M., & Reilmann, R. (2023). Contemporary pharmacological management of Huntington's disease. *Journal of Neurology*, 270(9), 4321–4335.
- Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., & McColgan, P. (2024). Gene-targeted therapies in Huntington's disease. *The Lancet Neurology*, 23(1), 55–71.
- World Health Organization. (2023). *Global status report on the public health response to dementia*. World Health Organization.
- Zerr, I., Villar-Piqué, A., Hermann, P., Schmitz, M., & Ladogana, A. (2020). Cerebrospinal fluid and blood biomarkers in prion diseases. *Nature Reviews Neurology*, 16(9), 539–552.